To win the battle with SARS-CoV-2 we need a therapeutic designed to regain control of immune response. Historically vaccines have played an important role in the prevention of many diseases. However, the overall effect of a vaccine within society depends on both efficacy and percent of the population that gets vaccinated.
For example, if the Pfizer vaccine is 90% effective, as projected, and half of the population receives the vaccine, over 50% of the population will remain unprotected.
Statistically, by easing compliance with mandates like wearing a mask, it is projected that up to 700,000 new cases of COVID-19 may take place in the US by December 31 of this year, per day.
https://www.statista.com/statistics/1176657/covid-projected-new-cases-per-day-by-scenario-us/
SAVRS-CoV-2 is an aggressive virus that thrives in the pulmonary system and leads to COVID-19. It overwhelms the body’s natural immune system, causes respiratory distress, respiratory failure, and potentially death. In addition to a vaccine, therapeutics are needed to reduce inflammation and viral load within the pulmonary system.
ENDECE did just that. We developed NDC-1308, a therapeutic that works at the gene level to reduce inflammation and viral load within the pulmonary system. Either alone or in combination with a vaccine, NDC-1308 may help to win the battle against viruses like SARS-CoV-2 / COVID-19 as well as any future SARS and pulmonary viruses causing Acute Respiratory Distress Syndrome (ARDS).